119 related articles for article (PubMed ID: 11264596)
41. Expression, refolding, purification, molecular characterization, crystallization, and preliminary X-ray analysis of the receptor binding domain of human B7-2.
Zhang X; Schwartz JC; Almo SC; Nathenson SG
Protein Expr Purif; 2002 Jun; 25(1):105-13. PubMed ID: 12071705
[TBL] [Abstract][Full Text] [Related]
42. CD28-independent costimulation of T cells in alloimmune responses.
Yamada A; Kishimoto K; Dong VM; Sho M; Salama AD; Anosova NG; Benichou G; Mandelbrot DA; Sharpe AH; Turka LA; Auchincloss H; Sayegh MH
J Immunol; 2001 Jul; 167(1):140-6. PubMed ID: 11418642
[TBL] [Abstract][Full Text] [Related]
43. Cutting edge: the relative distribution of T cells responding to chemically dominant or minor epitopes of lysozyme is not affected by CD40-CD40 ligand and B7-CD28-CTLA-4 costimulatory pathways.
DiPaolo RJ; Unanue ER
J Immunol; 2002 Sep; 169(6):2832-6. PubMed ID: 12218093
[TBL] [Abstract][Full Text] [Related]
44. Murine B7-2, an alternative CTLA4 counter-receptor that costimulates T cell proliferation and interleukin 2 production.
Freeman GJ; Borriello F; Hodes RJ; Reiser H; Gribben JG; Ng JW; Kim J; Goldberg JM; Hathcock K; Laszlo G
J Exp Med; 1993 Dec; 178(6):2185-92. PubMed ID: 7504059
[TBL] [Abstract][Full Text] [Related]
45. Costimulation light: activation of CD4+ T cells with CD80 or CD86 rather than anti-CD28 leads to a Th2 cytokine profile.
Broeren CP; Gray GS; Carreno BM; June CH
J Immunol; 2000 Dec; 165(12):6908-14. PubMed ID: 11120816
[TBL] [Abstract][Full Text] [Related]
46. Structure and dimerization of a soluble form of B7-1.
Ikemizu S; Gilbert RJ; Fennelly JA; Collins AV; Harlos K; Jones EY; Stuart DI; Davis SJ
Immunity; 2000 Jan; 12(1):51-60. PubMed ID: 10661405
[TBL] [Abstract][Full Text] [Related]
47. The tissue distribution of the B7-2 costimulator in mice: abundant expression on dendritic cells in situ and during maturation in vitro.
Inaba K; Witmer-Pack M; Inaba M; Hathcock KS; Sakuta H; Azuma M; Yagita H; Okumura K; Linsley PS; Ikehara S; Muramatsu S; Hodes RJ; Steinman RM
J Exp Med; 1994 Nov; 180(5):1849-60. PubMed ID: 7525841
[TBL] [Abstract][Full Text] [Related]
48. Acquisition of CD80 by human T cells at early stages of activation: functional involvement of CD80 acquisition in T cell to T cell interaction.
Tatari-Calderone Z; Semnani RT; Nutman TB; Schlom J; Sabzevari H
J Immunol; 2002 Dec; 169(11):6162-9. PubMed ID: 12444120
[TBL] [Abstract][Full Text] [Related]
49. B7-1 engagement of cytotoxic T lymphocyte antigen 4 inhibits T cell activation in the absence of CD28.
Fallarino F; Fields PE; Gajewski TF
J Exp Med; 1998 Jul; 188(1):205-10. PubMed ID: 9653097
[TBL] [Abstract][Full Text] [Related]
50. Induction of CD4 T cell changes in murine AIDS is dependent on costimulation and involves a dysregulation of homeostasis.
Yen MH; Lepak N; Swain SL
J Immunol; 2002 Jul; 169(2):722-31. PubMed ID: 12097374
[TBL] [Abstract][Full Text] [Related]
51. CD28-B7 interactions are not required for intrathymic clonal deletion.
Jones LA; Izon DJ; Nieland JD; Linsley PS; Kruisbeek AM
Int Immunol; 1993 May; 5(5):503-12. PubMed ID: 7686392
[TBL] [Abstract][Full Text] [Related]
52. Embryonic stem cells and embryoid bodies express lymphocyte costimulatory molecules.
Ling V; Munroe RC; Murphy EA; Gray GS
Exp Cell Res; 1998 May; 241(1):55-65. PubMed ID: 9633513
[TBL] [Abstract][Full Text] [Related]
53. Cutting edge: Cbl-b: one of the key molecules tuning CD28- and CTLA-4-mediated T cell costimulation.
Li D; Gál I; Vermes C; Alegre ML; Chong AS; Chen L; Shao Q; Adarichev V; Xu X; Koreny T; Mikecz K; Finnegan A; Glant TT; Zhang J
J Immunol; 2004 Dec; 173(12):7135-9. PubMed ID: 15585834
[TBL] [Abstract][Full Text] [Related]
54. B7 requirements for primary and secondary protein- and polysaccharide-specific Ig isotype responses to Streptococcus pneumoniae.
Wu ZQ; Khan AQ; Shen Y; Schartman J; Peach R; Lees A; Mond JJ; Gause WC; Snapper CM
J Immunol; 2000 Dec; 165(12):6840-8. PubMed ID: 11120807
[TBL] [Abstract][Full Text] [Related]
55. Interaction of CTLA-4 (CD152) with CD80 or CD86 inhibits human T-cell activation.
Vandenborre K; Van Gool SW; Kasran A; Ceuppens JL; Boogaerts MA; Vandenberghe P
Immunology; 1999 Nov; 98(3):413-21. PubMed ID: 10583602
[TBL] [Abstract][Full Text] [Related]
56. A chicken homologue of the co-stimulating molecule CD80 which binds to mammalian CTLA-4.
O'Regan MN; Parsons KR; Tregaskes CA; Young JR
Immunogenetics; 1999 Jan; 49(1):68-71. PubMed ID: 9811970
[No Abstract] [Full Text] [Related]
57. Expression of a hypoglycosylated form of CD86 (B7-2) on human T cells with altered binding properties to CD28 and CTLA-4.
Höllsberg P; Scholz C; Anderson DE; Greenfield EA; Kuchroo VK; Freeman GJ; Hafler DA
J Immunol; 1997 Nov; 159(10):4799-805. PubMed ID: 9366404
[TBL] [Abstract][Full Text] [Related]
58. CTLA-4 (CD152) can inhibit T cell activation by two different mechanisms depending on its level of cell surface expression.
Carreno BM; Bennett F; Chau TA; Ling V; Luxenberg D; Jussif J; Baroja ML; Madrenas J
J Immunol; 2000 Aug; 165(3):1352-6. PubMed ID: 10903737
[TBL] [Abstract][Full Text] [Related]
59. Absence of B7.1-CD28/CTLA-4-mediated co-stimulation in human NK cells.
Lang S; Vujanovic NL; Wollenberg B; Whiteside TL
Eur J Immunol; 1998 Mar; 28(3):780-6. PubMed ID: 9541571
[TBL] [Abstract][Full Text] [Related]
60. Hierarchical regulation of CTLA-4 dimer-based lattice formation and its biological relevance for T cell inactivation.
Darlington PJ; Kirchhof MG; Criado G; Sondhi J; Madrenas J
J Immunol; 2005 Jul; 175(2):996-1004. PubMed ID: 16002699
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
